Metabolic syndrome and mitochondrial dysfunction: insights from preclinical studies with a mitochondrially targeted antioxidant.
Center for Free Radical Biology, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Tanecia
T
Mitchell
Victor
V
Darley-Usmar
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001057:Apolipoproteins E / Q000235:genetics*; D064007:Ataxia Telangiectasia Mutated Proteins; D050197:Atherosclerosis / Q000188:drug therapy*; D018797:Cell Cycle Proteins / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000235:genetics*; D005260:Female; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy*; D008928:Mitochondria / Q000187:drug effects*; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D025521:Tumor Suppressor Proteins / Q000235:genetics*; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000494:pharmacology
D000975:Antioxidants; D001057:Apolipoproteins E; D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D009943:Organophosphorus Compounds; D025521:Tumor Suppressor Proteins; D014451:Ubiquinone; C429014:mitoquinone; D064007:Ataxia Telangiectasia Mutated Proteins; D017346:Protein Serine-Threonine Kinases